The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities.
The substitution, in the human V2 vasopressin receptor, of the aspartate at position 136 by alanine leads to agonist-independent activation of this mutant V2 receptor. Pharmacological studies of the D136A V2 receptor helped us in characterizing different V2 receptor antagonists. SR-121463A and OPC-31260, two non-peptide antagonists, behaved as inverse agonists, while two cyclic peptides d(CH2)5[D-Tyr(Et)2,-Val4,Tyr-NH(2)9]AVP and d(CH2)5[D-Ile2,Ile4,Tyr-NH(2)9]AVP known to be V2 antagonists, demonstrated clear partial agonist properties. The finding of a constitutively activated human V2 receptor represents a useful tool in characterizing V2 receptor antagonist ligands.
Morin
D
D
Unité INSERM 469, CCIPE, Montpellier, France. morin@u469.montp.inserm.fr
Cotte
N
N
Balestre
M N
MN
Mouillac
B
B
Manning
M
M
Breton
C
C
Barberis
C
C
D000595:Amino Acid Sequence; D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D019556:COS Cells; D000242:Cyclic AMP / Q000378:metabolism; D006801:Humans; D008969:Molecular Sequence Data; D016296:Mutagenesis; D011485:Protein Binding; D017483:Receptors, Vasopressin / Q000819:agonists / Q000235:genetics*
D065092:Antidiuretic Hormone Receptor Antagonists; D017483:Receptors, Vasopressin; D000242:Cyclic AMP